Altimmune, Inc. (NASDAQ:ALT) traded at $11.66 at last check on Monday, June 29, making an upward move of 7.28% on its previous day’s price.
Looking at the stock we see that its previous close was $10.6 and the beta (5Y monthly) reads 0.97 with the day’s price range being $11.11 – 12.74. In terms of its 52-week price range, ALT has a high of $12.74 and a low of $1.51. The company’s stock has gained about 29.58% over that past 30 days.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $500Million, with a low of $500Million and a high of $500Million. The median projection represents growth adding up to -69.2% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $3.7 Million, or -36.2% down from figures reported last year.
On the other hand, looking at the outlook for the ALT stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Altimmune, Inc. (ALT) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Let’s briefly compare Altimmune, (ALT) stock to its peers. We find that today’s price change of +7.28% and +358.87% over the past 12 months for ALT betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.01% in the latest trading session and is +17.65% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.42% today, and is +4.38% up over the past year, while Grifols S.A. (GRFS) is also up 7.28% yet its price remains in the green at 358.87% over the same period. Zoetis has a P/E ratio of 39.46 compared to Altimmune,’s 0 and Takeda’s 22.6. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.81% and 1.11%, respectively, in early deals.
Coming back to Altimmune, Inc. (NASDAQ:ALT), we note that the average 3-month trading volume was 2.77 Million, while that of the preceding 10-day period stands at 2.64 Million. Current shares outstanding are 21.61 Million.
According to data from Thomson Reuters, insiders hold 17.11% of the company’s shares while institutions hold 8.38%. The data shows that short shares as of June 14, 2020, stood at 2.64 Million at a short ratio of 0.54. This represents a 13.13% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 1.86 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +460.85% up in year-to-date price movement.